# US 2014/0242108 A1 · Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0242108 A1
- Document ID: US20140242108A1
- Status: Published application
- Kind: A1
- Application number: 13/774,155
- Filed: 2013-02-22
- Published: 2014-08-28
- Earliest claimed: 2013-02-22
- Assignees: Cayla
- Applicants: Cayla
- Inventors: Thierry LIOUX; Daniel DROCOURT; Fabienne VERNEJOUL; Gerard TIRABY; Eric PEROUZEL
- Web page: https://patentgrep.com/patent/US20140242108A1

## CPC

- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 31/52: Purines, e.g. adenine
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:

## Claims

### Claim 1

A conjugated compound of Formula I:
Q-Z—R4 Formula I
wherein Q is an imidazoquinoline, a purine or a 3-deazapurine derivative agonist of TLR7 and/or TLR8 t and Z—R4 is a TLR2 agonist,
said conjugated compound being chosen among compounds of Formula II:
a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer, wherein:
R1 is —H, —OH, —SH, —NH2, —CF3, halogen, or a group chosen from C1-C6alkyl, C1-C6alkylamino, C1-C6alkoxy, C3-C6cycloalkyl-C1-C6alkyl, C3-C6cycloalkyl-C1-C6alkylamino, C3-C6cycloalkyl, C1-C6alkoxyC1-C6alkylamino, or C1-C6alkoxyC1-C6alkoxy, (C1-C6alkyl)-E-(C1-C6alkylene)- wherein E is —O—, —S—, —N(R12)—, —C(O)— or —S(O)2— and R12 is —H, carboxyl, —NH2, C1-C6alkyl, C1-C6alkoxy, C1-C6alkanoyl, C6-C20aryl, C6-C20 heteroaryl, or C1-C6alkoxycarbonyl, said group being optionally terminally substituted with a hydroxyl, amino, thiol, hydrazino, hydrazido, azido, acetylenyl, carboxyl, or maleimido group;
A is a nitrogen atom, R3 is absent and R2 is H, OH, SH, NH2, CF3, halogen, C1-C10alkyl, C1-C10alkylamino, C1-C10dialkylamino, C1-C10alkoxy, C1-C10alkoxy-C1-C10 alkylamino, C1-C10alkoxy-C1-C10alkoxy, C1-C10alkoxy-C5-C7heterocycle, C1-C10alkyamino-C5-C7heterocycle, —NH—SO2—C1-C6alkyl, —C(O)—C1-C6alkyl, —O—C(O)—C1-C6alkyl, —C(O)—C1-C10alkylamino, —C(O)—C1-C10dialkylamino, C5-C10aryl, C5-C9heterocyclyl, C3-C9 carbocyclyl, C1-C10alkylamino-C2-C7heterocycle, (C1-C6alkoxy)-E-(C1-C6alkylene) and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, more preferably R1 is —OH, or
A is a carbon atom and R2 and R3 form together a fused phenyl optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CH3, —CH2CH3, CH2CH(CH3)2, —CH2OH, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CN, —CF3, —CHF2, —CO2H, —COCH3, —CO2CH2, —C(CH3)2CO2CH3, —CO2C(CH3)3, —COCH(OH) CH3, —COCH(CH3)2, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NO2, —NH2, —NHCH3, —N(CH2)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH2, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —OH, —OCH3, —S(O)2N (CH3)2, —SCH3, —CH2OCH3, —S(O)2CH3, cyclopropyl, oxetanyl, and morpholino, and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, or
A is a carbon atom and R2 and R3 independently from each other are H, OH, SH, NH2, CF3, halogen, C1-C10alkyl, C1-C10alkylamino, C1-C10dialkylamino, C1-C10alkoxy, C1-C10alkoxy-C1-C10 alkylamino, C1-C10alkoxy-C1-C10alkoxy, C1-C10alkoxy-C5-C7heterocycle, C1-C10alkyamino-C5-C7heterocycle, —NH—SO2—C1-C6alkyl, —C(O)—C1-C6alkyl, —O—C(O)—C1-C6alkyl, —C(O)—C1-C10alkylamino, —C(O)—C1-C10dialkylamino, C5-C10aryl, C5-C9heterocyclyl, C3-C9 carbocyclyl, C1-C10alkylamino-C2-C7heterocycle, (C1-C6alkoxy)-E-(C1-C6alkylene) and preferably R1 is —H, —OH, —SH, —NH2, C1-C6alkyl, such as methyl, ethyl, propyl or butyl, C1-C6alkylamino such as methylamino, ethylamino, propylamino or butylamino, C1-C6alkoxy such as methoxy, ethoxy, propoxy or butoxy, (C1-C6alkyl)-E-(C1-C6alkylene), wherein E is —O— or —NH—, such as —CH2—NH—C2H5, —CH2—O—C2H5, —(CH2)2—NH—CH3, or —(CH2)2—O—CH3, more preferably R1 is —OH, and
s is an integer from 1 to 4;
X is an unbranched —(C1-C6 alkylene)-, —(C6-C20arylene)-, —(C4-C20heteroarylene)-, —(C1-C6 alkylene)-E-(C1-C6 alkylene)-, —(C1-C6 alkylene)-(C3-C7-carbocyclylene)-, —(C1-C6 alkylene)-(C3-C7-heterocyclylene)-, —(C1-C6 alkylene) —(C6-C20 arylene)-, —(C1-C6 alkylene) —(C4-C20 heteroarylene)-, —(C1-C6 alkylene)-E-(C1-C7 carbocyclylene)-, —(C1-C6 alkylene)-E-(C3-C7-heterocyclylene)-, —(C1-C6 alkylene)-E-(C6-C20 arylene)-, —(C1-C6 alkylene)-E-(C4-C20 heteroarylene)-, where alkylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CH3, —CH2CH3, CH2CH(CH3)2, —CH2OH, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CN, —CF3, —CHF2, —CO2H, —COCH3, —CO2CH3, —C(CH3)2CO2CH3, —CO2C(CH3)3, —COCH(OH) CH3, —COCH(CH3)2, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NO2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3) COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —OH, —OCH3, —S(O)2N (CH3)2, —SCH3, —CH2OCH3, S(O)2CH3, cyclopropyl, oxetanyl, and morpholino, and E is as defined above;
Y is a single bond, —O—, —S—, —N(R12)—, —C(O)—, or —S(O)2— and R12 is as defined above;
Z—R4 is a TLR2 agonist selected from the group consisting of:
wherein:
R5 and R6, identical or different, are the specific side chain of an amino acid;
W is —O—, —NH—, or —S—;
j and 1, identical or different, are 0 or 1;
p is integer from 0 to 6;
f, g, k, m, n, o, and q, identical or different, are integers from 1 to 4;
r and t, identical or different, are integers from 1 to 6; and
R4 is a lipid of Formula XI:
wherein:
R7 and R8 are independently from each other H, C1-C30alkyl, C2-C30alkylenyl, —C(O)—C1-C30alkyl, —C(O)—C2-C30alkylenyl, or —C(O)—O—C1-C30alkyl;
R9 is H, C1-C30alkyl or C2-C30alkylenyl;
R10 is H, C1-C30alkyl or C2-C30alkylenyl;
R9 and R10 are not both H;
L1 is absent, —OC(O)—, —O—, —NR11C(O)—, —OC(O)NR11— or —CH2- wherein R11 is H, C1-C30alkyl or C2-C30alkylenyl;
L2 is —CH2OC(O)—, —CH2O—, —CH2NR11C(O)— or —CH2—, if L1 is absent L2 is —OC(O)—, —O—, —NR11C(O)—, —NR10R11, —OC(O)NR11— or —CH2- wherein R11 is as defined above.

### Claim 2 (depends on 1)

The conjugated compound according to claim 1, wherein s is 1.

### Claim 3 (depends on 1)

The conjugated compound according to claim 1, wherein X is a —(C6-C20arylene), preferably a phenylene, a —(C1-C6 alkylene)-, preferably an ethylene or a propylene, or a —(C4-C20heteroarylene)-, preferably a pyridinylene, a pyrimidinylene, or a pyridazylene).

### Claim 4 (depends on 1)

The conjugated compound according to claim 1, wherein Y is —NH—, —O—, —S—, or —C(O)—, in particular —NH— or —C(O)—.

### Claim 5 (depends on 1)

The conjugated compound according to claim 1, wherein:
Z is of formula III wherein 1=1, R5═H, m=3, n=4,p=1, o=3 and j=0 or 1 and q=2;
Z is of formula IV wherein 1=0 or 1, R5═H, W═NH, q=4, m=3, n=4 p=1, and o=3;
Z is of formula V wherein 1=0 or 1, R5═H, W═NH or O, q=1 or 4, m=3, n=4, p=1, and o=3;
Z is of formula VI wherein 1=0, q=2, m=3, n=4, p=1, and o=3;
Z is of formula VII wherein 1=0, q=2, m=3, n=4, p=1, and o=3;
Z is of formula VIII wherein R6=—CH2—OH, k=1, r=4, q=4, l=0.
Z is of formula IX wherein R6=—CH2—OH, k=1, q=4, l=0, r=3, f=4 or
Z is of formula X wherein R6=—CH2—OH, k=1, q=4, r=1 or 2, f=4, l=0, g=4, t=1 or 2.

### Claim 6 (depends on 1)

The conjugated compound according to claim 1, wherein R4 is a lipid of formula XI wherein:
R7 and R8 are independently from each other H or —C(O)—C1-C30alkyl such as —COCH3, —COC13H27, —COC15H31, or —COC17H35;
R9 and R10 are independently from each other H or C1-C30alkyl, such as —C13H27, —C15H31, or —C17H35;
R9 and R10 are not both H and
L1 is absent and L2 is —OC(O)—; or
L1 and L2 are —OC(O)—.

### Claim 7 (depends on 1)

The conjugated compound according to claim 1, wherein said conjugated compound is selected from the group consisting of:
(20R)-20-amino-1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4,19-trioxo-22-thia-2,5,9,14,18-pentaazapentacosane-24,25-diyl dipalmitate,
(20R)-1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4,19-trioxo-20-palmitamido-22-thia-2,5,9,14,18-pentaazapentacosane-24,25-diyl dipalmitate,
(6R,9S)-6,23-diamino-9-((4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzoyloxy)methyl)-7,10-dioxo-4-thia-8,11,15,20-tetraazatricosane-1,2-diyl dipalmitate,
(6R,13S)-6,27-diamino-13-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)-7,14-dioxo-4-thia-8,15,19,24-tetraazaheptacosane-1,2-diyl dipalmitate,
(6R,13S)-6,27-diamino-13-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)-7,14-dioxo-4-thia-8,15,19,24-tetraazaheptacosane-1,2-diyl dipalmitate,
(6R,9S)-6,23-diamino-9-(4-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)butyl)-7,10-dioxo-4-thia-8,11,15,20-tetraazatricosane-1,2-diyl dipalmitate,
(6R,9S)-6,25-diamino-9-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl carbamoyl)-7,12-dioxo-4-thia-8,13,17,22-tetraazapentacosane-1,2-diyl dipalmitate,
(6S,9S,12S,15S,18S,21R)-6,25-diamino-21-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-12,15,18-tris(4-aminobutyl)-9-(hydroxymethyl)-7,10,13,16,19-pentaoxo-4-thia-8,11,14,17,20-pentaazapentacosane-1,2-diyl dipalmitate,
(2S,5S,8S,11S,14S,17R)-17-amino-5-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,8,11-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-pentaazanona triacontan-1-oic acid,
(2S,5S,8S,11S,14S,17R)-17-amino-5-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,8,11-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-pentaazanona triacontan-1-oic acid,
(2S,5S,8S,11S,14S,17R)-17-amino-11-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,5,8-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-pentaazanona triacontan-1-oic acid,
((6R,9S,12S,15S,18S,21S)-25-amino-21-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-12,15,18-tris(4-aminobutyl)-9-(hydroxymethyl)-7,10,13,16,19-pentaoxo-6-palmitamido-4-thia-8,11,14,17,20-pentaazapentacosane-1,2-diyl dipalmitate,
(2S,5S,8S,11S,14S,17R)-5-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,8,11-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-17-palmitamido-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-penta azanonatriacontan-1-oic acid,
(2S,5S,8S,11S,14S,17R)-8-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,5,11-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-17-palmitamido-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-penta azanonatriacontan-1-oic acid,
(2S,5S,8S,11S,14S,17R)-11-(4-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)butyl)-2,5,8-tris(4-aminobutyl)-14-(hydroxymethyl)-4,7,10,13,16,24-hexaoxo-17-palmitamido-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-penta azanonatria contan-1-oic acid, and
(S)-methyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-22-((R)-2-amino-3-(2-(tetradecanoyloxy)ethylthio)propanamido)-1,4,19-trioxo-2,5,9,14,18-pentaazatricosan-23-oate,
a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

### Claim 8 (depends on 1)

A compound of formula XIII:
H—Z—R4 Formula XIII
a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer, wherein Z—R4 is as defined in claim 1, said compound being an agonist of TLR2.

### Claim 9 (depends on 8)

The compound of formula XIII according to claim 8, said compound being selected from the group consisting of:
(6R)-6,20-diamino-7-oxo-4-thia-8,12,17-triazaicosane-1,2-diyl dipalmitate
(6R)-20-amino-7-oxo-6-palmitamido-4-thia-8,12,17-triazaicosane-1,2-diyl dipalmitate,
(6R,9S)-6,23-diamino-9-(hydroxymethyl)-7,10-dioxo-4-thia-8,11,15,20-tetraazatri cosane-1,2-diyl dipalmitate,
(6R,13S)-6,13,27-triamino-7,14-dioxo-4-thia-8,15,19,24-tetraazaheptacosane-1,2-diyl dipalmitate
(6R,9S)-6,23-diamino-9-(4-aminobutyl)-7,10-dioxo-4-thia-8,11,15,20-tetraazatricosane-1,2-diyl dipalmitate,
(2S)-2-((2R)-2-amino-3-(2,3-bis(palmitoyloxy)propylthio)propanamido)-5-(3-(4-(3-aminopropylamino)butylamino)propylamino)-5-oxopentanoic acid, and
(5R,8S)-5,24-diamino-8-(methoxycarbonyl)-6,11-dioxo-3-thia-7,12,16,21-tetraaza tetracosyl tetradecanoate.

### Claim 10 (depends on 1)

A process for the manufacture of the compounds of formula II according to claim 1, which process comprises reacting a compound of Formula XII:
wherein R1, R2, R3, A, s, X and Y are as previously defined,
with a compound of Formula XIII:
H—Z—R4 Formula XIII
wherein Z and R4 are as previously defined, or reacting a compound of Formula XIV:
wherein R1, R2, R3, A, s, X, Y and Z are as previously defined, and P2 is a protecting group, with a compound of Formula XV:
HO—R4 Formula XV
wherein R4 is as defined above, followed by a deprotection step.

### Claim 11 (depends on 1)

A complex formed between a polyanionic molecule such as a nucleic acid molecule and the compound according to claim 1 in a medium having a pH comprised between 4 and 8.

### Claim 12 (depends on 8)

A complex formed between a polyanionic molecule such as a nucleic acid molecule and the compound according to claim 8 in a medium having a pH comprised between 4 and 8.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1, in particular in the form of a complex with a polyanionic molecule, and a pharmaceutically acceptable excipient or carrier.

### Claim 14 (depends on 8)

A pharmaceutical composition comprising the compound according to claim 8, in particular in the form of a complex with a polyanionic molecule, and a pharmaceutically acceptable excipient or carrier.

### Claim 15 (depends on 1)

A vaccine comprising the compound according to claim 1, in particular in the form of a complex with a polyanionic molecule.

### Claim 16 (depends on 8)

A vaccine comprising the compound according to claim 8, in particular in the form of a complex with a polyanionic molecule.

### Claim 17 (depends on 1)

A method for treating pathology selected from the group consisting of an infection, a cancer and an immune disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of the compound according to claim 1, in particular in the form of a complex with a polyanionic molecule.

### Claim 18 (depends on 8)

A method for treating an infection, a cancer and an immune disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of the complex according to claim 8, in particular in the form of a complex with a polyanionic molecule.

### Claim 19 (depends on 1)

A method for inducing an immune response via TLR7 and/or TLR8 and TLR2 and/or cytosolic nucleic acids sensors pathway(s) in a patient, comprising administering to said patient a therapeutically effective amount of the conjugated compound according to claim 1, in particular in the form of a complex with a polyanionic molecule.

### Claim 20 (depends on 8)

A method for inducing an immune response via TLR2 and/or cytosolic nucleic acids sensors pathway(s) in a patient, comprising administering to said patient a therapeutically effective amount of the compound according to claim 8, in particular in the form of a complex with an polyanionic molecule.
